688079MediKai as of December 06, 2021 financing balance of 73.88 million yuan, down 0.29% from the previous day, the financing balance of the two financial standards ranked 1,865; the balance of 29.22 million yuan of fusion bonds, fusion bond balance of 2.03 million shares, a decline of 6.21% from the previous day, the fusion bond balance of the two fusion standards ranked 491st.
MediKai (688079.sh) announced that Mr. Ge Wenzhi, the actual controller, chairman and general manager of the company, increased his shareholding by 150,000 shares from Sep 17, 2021 to Sep 24, 2021, accounting for 0.0374% of the total shares of the company, and the cumulative increase in shareholding was RMB 2.402 million. The actual amount of share increase by Mr. Ge Wenzhi has exceeded 50% of the minimum amount of the share increase plan, which has not yet been completed.
The company plans to set up a subsidiary, use its own or self-financed funds to purchase land to build a factory, and introduce advanced production and testing equipment, including photolithography, dry etching machines, coating machines, etc.. Focusing on the development and production of CIS IC wafer optical circuit layer, environmental optical circuit layer, RF chip and power device chip microcircuit, semiconductor packaging and measurement, to promote the company's sustained high-quality development. The total investment of the project is about 1 billion yuan, of which about 850 million yuan of fixed assets investment.
As of the date of disclosure of this announcement, Ge Wenzhi holds 55.62% of the voting rights of the company. Among them, Lishui Medecai Investment Partnership (limited partnership) holds 165,196,355 shares, accounting for 41.16%; through medicai holding group limited company control company 27,628,736 shares, accounting for 6.88%; through jingning double investment partnership (limited partnership) control company 19,510,584 shares, accounting for 4.86%; through lishui incremental investment partnership (limited Partnership) controls 5,525,747 shares of the Company, accounting for 1.38%; through Lishui Share Investment Partnership (Limited Partnership) controls 2,762,874 shares of the Company, accounting for 0.69%; through Haining Medical Finance Investment Partnership (Limited Partnership) controls 2,592,404 shares of the Company, accounting for 0.65%.
The company's 2021 semi-annual report shows that in the first half of 2021, the company's net profit attributable to shareholders of listed companies was 47497958.78 yuan, a year-on-year decline of 32.16%.
MediKai announced that in order to improve the industrial layout and enrich the product structure, the company intends to set up a controlling subsidiary "Meditec (Zhejiang) Intelligent Optoelectronics Co. (hereinafter referred to as the "joint venture"), the registered capital of 12 million U.S. dollars, the company will invest 9.6 million U.S. dollars in the form of currency, holding 80% of the equity of the joint venture.
It is reported that the joint venture will be based on the company's existing business, focusing on the development of mobile communications, smart wear, automotive applications in the visual sensor components; automotive, marine, railroad and other transportation applications dedicated laser lighting and display equipment; prisms, light guiding lenses, optical lenses and coating customized modules in the industrial automation, smart phones and other smart devices.